# South Korea Biosimilar Contract Manufacturing Market > South Korea Biosimilar Contract Manufacturing Market Research Report: Size, Share, Trend Analysis By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian) and By Applications (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic & Autoimmune Disorders, Rheumatoid Arthritis, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 18.9% - **2024:** $ 115.93 Million - **2025:** $ 137.84 Million - **2035:** $ 778.53 Million - **Key Players:** Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Wuxi Biologics (CN), Roche (CH), Amgen (US), Sandoz (CH) **Report ID:** MRFR/MED/50108-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-biosimilar-contract-manufacturing-market-51866 --- ## Market Summary ## **South Korea Biosimilar Contract Manufacturing Market Overview** As per MRFR analysis, the South Korea Biosimilar Contract Manufacturing Market Size was estimated at 130.03 (USD Million) in 2023. The South Korea Biosimilar Contract Manufacturing Market Industry is expected to grow from 154.6(USD Million) in 2024 to 1,097.6 (USD Million) by 2035. The South Korea Biosimilar Contract Manufacturing Market CAGR (growth rate) is expected to be around 19.505% during the forecast period (2025 - 2035). ### **Key South Korea Biosimilar Contract Manufacturing Market Trends Highlighted** The South Korea Biosimilar Contract Manufacturing Market is currently experiencing significant market trends that are being driven by the increasing emphasis on affordable treatment options and the growth in healthcare expenditures. The South Korean government has been supportive of biosimilars through a variety of initiatives, with the objective of enhancing access to biologic therapies. Pharmaceutical companies are being incentivized to invest in biosimilar development and contract manufacturing capabilities within the country as a result of the favorable regulatory environment. Furthermore, the expansion of biopharmaceutical manufacturing facilities is a substantial trend, as companies strive to improve their production capacity and efficiency in order to satisfy the increasing global demand. As an increasing number of global pharmaceutical companies seek local partners for contract manufacturing services, opportunities in the South Korean biosimilar market are arising. The country's state-of-the-art technologies, skilled workforce, and advanced biomanufacturing infrastructure make a compelling argument for attracting foreign investment. Additionally, the growing partnership between international corporations and local biopharmaceutical companies is facilitating the development of innovative production processes and biosimilars. Recently, there has been a discernible trend in South Korea towards the acceleration of biosimilar research and development through collaboration between academia and the biopharmaceutical industry. It is anticipated that this trend will facilitate the commercialization of novel biosimilar products. Moreover, the demand for biosimilars, which are less expensive than biologic medications, is expected to increase as healthcare providers and patients become more cognizant of their advantages. In general, the South Korean Biosimilar Contract Manufacturing Market is experiencing growth, which is being driven by a robust manufacturing sector, supportive policies, and a growing number of collaborations that are designed to advance the biosimilar landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** ### **South Korea Biosimilar Contract Manufacturing Market Drivers** #### **Increasing Demand for Biologics** The South Korea Biosimilar Contract Manufacturing Market is experiencing significant growth driven by the increasing demand for biologics. According to the South Korean Ministry of Health and Welfare, the annual expenditure on biologics reached approximately 3.3 trillion KRW in recent years, with projections indicating a continual increase as the population ages and chronic diseases rise. Major pharmaceutical companies, like Samsung Bioepis and Celltrion, have been proactively expanding their production capabilities to meet this growing demand. This trend is supported by a government initiative to increase the production of domestically developed biopharmaceuticals, creating a conducive environment for biosimilar production and contract manufacturing. #### **Supportive Regulatory Framework** The South Korea Biosimilar Contract Manufacturing Market is heavily influenced by the supportive regulatory landscape that encourages biosimilar development. The Ministry of Food and Drug Safety in South Korea has established clear guidelines and fast-track processes for biosimilars, facilitating quicker market entry for these products. As an example, the number of approved biosimilars in the country surged to over 30 in recent years, reflecting the robust pathways established for biosimilar approval and regulatory compliance. This acceleration in approval rates not only enhances the operational landscape for contract manufacturers but also fosters a competitive market conducive to growth. #### **Rising Chronic Disease Prevalence** The prevalence of chronic diseases in South Korea is a pivotal driver for the growth of the Biosimilar Contract Manufacturing Market Industry. Statistics from the Korea Centers for Disease Control and Prevention reveal that the rates of conditions such as diabetes and cardiovascular diseases have increased significantly, leading to a larger population requiring biologic treatments. Furthermore, the World Health Organization estimates a projected 20% increase in the number of patients suffering from chronic diseases in South Korea over the next decade. This growing health burden necessitates cost-effective treatment options, positioning biosimilars as crucial alternatives, thereby enhancing the demand for contract manufacturing services within the region. ### **South Korea Biosimilar Contract Manufacturing Market Segment Insights** #### **Biosimilar Contract Manufacturing Market Product Insights** The South Korea Biosimilar Contract Manufacturing Market is characterized by a well-defined product segmentation, prominently featuring Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins. Recombinant Non-glycosylated Proteins serve as a critical component due to their role in several therapeutic applications, often offering a more streamlined production process and decreased costs for manufacturers. This segment is gaining traction as companies aim to create cost-effective solutions, contributing to the overall efficiency in biopharmaceutical development. Furthermore, Recombinant Glycosylated Proteins hold significant importance as they closely mimic natural proteins, proving essential in developing complex biologics that require specific glycosylation patterns for functionality and efficacy. The strategic position of South Korea as a hub for biomanufacturing enhances the capabilities of these subcategories, driven by a robust Research and Development infrastructure supported by governmental incentives aimed at fostering innovation. The country’s focus on enhancing manufacturing technologies positions it favorably for growth in the biosimilar sector, particularly in producing high-quality biologics that meet international standards. Market dynamics reveal a growing demand for biosimilars as healthcare costs continue to rise globally, with South Korea emerging as a leader due to its advanced manufacturing capabilities and a supportive regulatory environment that encourages biosimilar production. Moreover, both segments are witnessing an increase in investment and partnerships that facilitate technological advancements, thereby enhancing their contributions to the South Korea Biosimilar Contract Manufacturing Market. The market is also propelled by factors such as an aging population, increased prevalence of chronic diseases, and a proactive healthcare policy that emphasizes accessibility and affordability of biologic therapies. As these segments continue to evolve, they promise to play a vital role in the overall expansion of the biosimilar landscape in South Korea, catering to both domestic and international demands and significantly influencing the country's economic growth in the healthcare sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review** #### **Biosimilar Contract Manufacturing Market Production Technology Insights** The Production Technology segment of the South Korea Biosimilar Contract Manufacturing Market showcases significant innovation and expansion. In South Korea, this market has seen a robust evolution, driven by advancements in biotechnology and a growing demand for cost-effective biosimilars. The country’s strong emphasis on Research and Development has propelled the growth of the mammalian production systems, which are crucial for producing complex biologics such as monoclonal antibodies. The demand for high-quality, reliable biosimilars ensures that mammalian systems maintain a prominent position in the market. Meanwhile, non-mammalian production technologies, such as those utilizing microorganisms or plant systems, are gaining traction, offering scalability and efficiency for various applications. This diversification in production methodologies not only enhances the supply chain resilience but also responds to the increasing global competition in the biopharmaceutical sector. As regulatory frameworks evolve, South Korea's proactive approach to biosimilar development positions it as a key player on the global stage, ensuring the Production Technology segment remains integral to the overall market progression. The continuous advancements in biotechnology signify substantial opportunities for optimization within both mammalian and non-mammalian production technologies, leading to improved productivity and reduced time-to-market for biosimilars. #### **Biosimilar Contract Manufacturing Market Application Insights** The South Korea Biosimilar Contract Manufacturing Market, particularly in the Application segment, exhibits significant potential and is driven by diverse therapeutic areas, including Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, and Rheumatoid Arthritis, among others. Oncology remains a crucial focus due to the high prevalence of cancer and the demand for cost-effective biologics to improve patient outcomes. Blood Disorders, such as hemophilia, constitute a vital segment, presenting strong opportunities for biosimilars designed to manage chronic conditions. Growth Hormonal Deficiency applications cater to pediatric and adult populations, highlighting the importance of biosimilars in promoting metabolic health. Chronic and Autoimmune Disorders form a considerable part of the clinical landscape, requiring ongoing management through biologic therapies. The Rheumatoid Arthritis segment is particularly noteworthy, reflecting the growing number of patients requiring long-term treatment plans. The South Korean government supports biosimilar development through favorable regulations aimed at accelerating market entry, enhancing the competitive edge of local manufacturers. As a result, the Application segment within the South Korea Biosimilar Contract Manufacturing Market displays robust growth potential, driven by an aging population, increasing healthcare expenditures, and a rising preference for biosimilars due to their affordability compared to originator biologics. ### **South Korea Biosimilar Contract Manufacturing Market Key Players and Competitive Insights** The South Korea Biosimilar Contract Manufacturing Market has become a dynamic and competitive landscape characterized by rapid advancements in biotechnology and an increasing demand for cost-effective therapeutic alternatives. As the global focus shifts towards biosimilars due to their potential to enhance patient access to biologic therapies, South Korea has positioned itself as a leader in the biosimilar industry. The convergence of government support, strong research and development capabilities, and a robust regulatory framework has facilitated a conducive environment for both established firms and new entrants. The competitive landscape is marked by a blend of local companies, which leverage technological expertise and innovation, as well as multinational corporations seeking to capitalize on the region’s strategic advantages. Severance Hospital has a notable presence in the South Korea Biosimilar Contract Manufacturing Market, thus strengthening the local healthcare infrastructure. The facility is recognized for its integration of cutting-edge research and clinical practices, which contributes significantly to the development and manufacturing of biosimilars. Its strengths lie in its comprehensive approach to patient care and the establishment of collaborations with various research entities, driving innovation in treatment modalities. The hospital’s commitment to advancing biopharmaceutical sciences is complemented by access to world-class expertise in therapeutics, clinical trials, and regulatory affairs, thereby facilitating moldable pathways for biosimilar product development and effective market navigation. Celltrion stands out as a pivotal player in the South Korea Biosimilar Contract Manufacturing Market, enjoying a favorable reputation for its high-quality biosimilars and a wide array of offerings. The company specializes in the production of monoclonal antibodies and has successfully launched several biosimilar products in both domestic and international markets. Key strengths include its state-of-the-art manufacturing facilities, which utilize advanced technologies that meet stringent regulatory standards. Celltrion has also engaged in strategic mergers and acquisitions to expand its operational capabilities and market reach, fortifying its competitive advantage. By establishing partnerships with various stakeholders, Celltrion demonstrates its commitment to innovation and sets a benchmark for quality in biosimilar manufacturing, solidifying its standing within the South Korean market. #### **Key Companies in the South Korea Biosimilar Contract Manufacturing Market Include** ### **South Korea Biosimilar Contract Manufacturing Market Industry Developments** Recent developments in the South Korea Biosimilar Contract Manufacturing Market have been significant, showcasing the country's prowess in biotechnology. Samsung BioLogics has been actively expanding its contract manufacturing capabilities, aiming to meet the increasing global demand for biosimilars. In October 2023, Celltrion announced a collaboration with a prominent European pharmaceutical company to enhance its biosimilar portfolio, reinforcing its position in the competitive landscape. Severance Hospital and the Korean Cancer Center Hospital have been integral in advancing clinical trials for biosimilars, ensuring regulatory compliance and safety. The market has seen a substantial growth in valuation, driven by innovations from Hanmi Pharmaceutical and Alteogen, who are investing heavily in Research and Development to optimize their offerings. Furthermore, Yuhan Corporation and SK Holdings are positioning themselves strategically through partnerships and technology sharing. In July 2022, LG Chem announced a merger with Ilyang Pharmaceutical to enhance production efficiencies and broaden its reach in biosimilar manufacturing. This collaborative environment is fostering a robust ecosystem that propels South Korea as a global leader in biomanufacturing and biosimilars, positioning companies like Medytox and DaeWoong Pharmaceutical favorably in the expanding market. ### **South Korea Biosimilar Contract Manufacturing Market Segmentation Insights** #### **Biosimilar Contract Manufacturing Market Product Outlook** #### **Biosimilar Contract Manufacturing Market Production Technology Outlook** #### **Biosimilar Contract Manufacturing Market Application Outlook** ## Market Drivers ### Increasing Healthcare Expenditure The rising healthcare expenditure in South Korea is a pivotal driver for the biosimilar contract-manufacturing market. As the government allocates more funds towards healthcare, the demand for affordable treatment options intensifies. In 2025, healthcare spending is projected to reach approximately $200 billion, reflecting a growth rate of around 5% annually. This increase in expenditure is likely to encourage healthcare providers to adopt biosimilars, which are generally more cost-effective than their reference biologics. Consequently, contract manufacturers are positioned to benefit from this trend, as they can offer tailored solutions to meet the growing demand for biosimilars. Thus, the biosimilar contract-manufacturing market is expected to expand. This growth is driven by the need for efficient production capabilities that align with the increasing healthcare budget. ### Regulatory Framework Enhancements Enhancements in the regulatory framework surrounding biosimilars in South Korea are fostering growth in the biosimilar contract-manufacturing market. The government has implemented streamlined approval processes and guidelines that facilitate the entry of biosimilars into the market. These regulatory improvements are designed to ensure safety and efficacy while expediting the availability of biosimilars to patients. As a result, the number of approved biosimilars has increased, leading to a more competitive market landscape. This regulatory support is likely to encourage contract manufacturers to invest in biosimilar production, as they can navigate the approval process more efficiently. The biosimilar contract-manufacturing market is thus benefiting from a more favorable regulatory environment that promotes innovation and accessibility. ### Aging Population and Chronic Diseases The aging population in South Korea is a critical driver for the biosimilar contract-manufacturing market. With a significant portion of the population over 65 years old, the prevalence of chronic diseases such as diabetes and cancer is on the rise. This demographic shift is expected to increase the demand for biologic therapies, including biosimilars, which are often more affordable alternatives. By 2025, it is estimated that nearly 20% of the population will be aged 65 and older, further amplifying the need for cost-effective treatment options. As healthcare providers seek to manage the growing burden of chronic diseases, the biosimilar contract-manufacturing market is poised for expansion, driven by the need for scalable production of these essential therapies. ### Growing Focus on Personalized Medicine The growing focus on personalized medicine in South Korea is emerging as a significant driver for the biosimilar contract-manufacturing market. As healthcare shifts towards tailored therapies that cater to individual patient needs, the demand for biosimilars that can be customized is likely to increase. This trend is supported by advancements in genomics and biotechnology, which enable the development of more targeted treatments. The biosimilar contract-manufacturing market is expected to adapt to this shift by offering flexible manufacturing solutions that accommodate the production of personalized biosimilars. As healthcare providers seek to enhance patient outcomes through personalized approaches, the demand for contract manufacturing services in the biosimilar sector is anticipated to grow. ### Technological Advancements in Manufacturing Technological advancements in biomanufacturing processes are significantly influencing the biosimilar contract-manufacturing market. Innovations such as single-use technologies and continuous manufacturing are enhancing production efficiency and reducing costs. In South Korea, the adoption of these technologies is becoming more prevalent, with a reported increase in productivity by up to 30% in some facilities. This shift not only streamlines operations but also allows for quicker responses to market demands. As manufacturers leverage these advancements, they can produce high-quality biosimilars at a lower cost, making them more accessible to healthcare providers. Thus, the biosimilar contract-manufacturing market is likely to grow as companies invest in cutting-edge technologies to enhance their production capabilities. ## Future Outlook The [Biosimilar Contract Manufacturing Market](https://www.marketresearchfuture.com/reports/biosimilar-contract-manufacturing-market-11903) is projected to grow at 18.9% CAGR from 2025 to 2035, driven by increasing demand for cost-effective biologics and regulatory support. **New opportunities:** - Invest in advanced bioreactor technologies to enhance production efficiency. - Develop strategic partnerships with local biotech firms for market penetration. - Implement robust quality assurance systems to meet regulatory compliance and build trust. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in biopharmaceutical manufacturing. ## Segment Insights ### By Product: Recombinant Non-glycosylated Proteins (Largest) vs. Recombinant Glycosylated Proteins (Fastest-Growing) In the South Korea biosimilar contract-manufacturing market, recombinant non-glycosylated proteins hold the largest market share, reflecting their established presence and adoption among consumers. These proteins are widely used in various therapeutic applications, giving them an edge in market demand. On the other hand, recombinant glycosylated proteins, although currently smaller in share, are rapidly gaining traction due to their enhanced efficacy and specificity, making them appealing for progressive biotechnology firms. Growth trends in this segment are buoyed by advancements in biomanufacturing technologies and increased investments in biosimilar development by key players. The demand for innovative therapies is leading to a surge in the development of recombinant glycosylated proteins, which are expected to witness the highest growth rates. Factors such as rising healthcare needs and supportive government policies for biosimilars are further propelling this market segment's expansion. Recombinant Non-glycosylated Proteins (Dominant) vs. Recombinant Glycosylated Proteins (Emerging) Recombinant non-glycosylated proteins are currently the dominant force in the South Korea biosimilar contract-manufacturing market, characterized by their reliable performance in therapeutic applications including hormones and enzymes. Their established manufacturing processes and regulatory approvals contribute to their widespread acceptance. In contrast, recombinant glycosylated proteins represent an emerging category, known for their uniquely advanced functionality in mimicking natural proteins, crucial in treating diseases with high specificity. The growing interest in personalized medicine and the drive for more complex biologics enhances the potential for recombinant glycosylated proteins, setting the stage for them to become significant players in the biosimilar landscape. ### By Production Technology: Mammalian (Largest) vs. Non-Mammalian (Fastest-Growing) In the South Korea biosimilar contract-manufacturing market, the production technology segment reveals a distinct division between mammalian and non-mammalian technologies. The mammalian segment holds the largest market share, favored for its ability to produce complex proteins that resemble human biology closely. This preference translates into a significant portion of the market, as biopharmaceutical companies increasingly rely on mammalian cells for high-quality biosimilar development. Conversely, non-mammalian technologies, while currently smaller in terms of market share, are recognized as the fastest-growing segment. The rise of these technologies aligns with innovations aimed at reducing production costs and time, making them attractive for companies focused on efficiency and scalability. As regulatory agencies continue to evolve, non-mammalian processes are expected to gain traction, driven by their potential to enhance production flexibility and throughput. Production Technology: Mammalian (Dominant) vs. Non-Mammalian (Emerging) Mammalian production technology dominates the South Korea biosimilar contract-manufacturing market, primarily due to its established processes and proven track record in producing high-quality therapeutic proteins. This dominance reflects the growing demand for complex biologics that require intricate post-translational modifications, which mammalian systems are well-equipped to handle. On the other hand, non-mammalian technology is emerging rapidly, characterized by its promise of lower production costs and faster turnaround times. As these technologies continue to mature, they are expected to carve out their niche in the market, appealing to cost-sensitive manufacturers and those looking to innovate their production pipelines. This dynamic between dominant and emerging technologies highlights the competitive landscape in the market. ### By Application: Oncology (Largest) vs. Chronic & Autoimmune Disorders (Fastest-Growing) In the South Korea biosimilar contract-manufacturing market, the application segment is diverse, with oncology representing the largest share of the market. This segment showcases strong demand driven by the increasing incidence of cancer and the need for effective treatments. Blood disorders and growth hormonal deficiency also hold notable shares, while chronic & autoimmune disorders, rheumatoid arthritis, and others follow closely behind in terms of market presence. Growth trends indicate a significant shift towards chronic & autoimmune disorders, positioning it as the fastest-growing application. This rise is attributed to the increasing prevalence of autoimmune diseases and advancements in biosimilar technologies. Additionally, the health policies in South Korea favoring cheaper treatment options support the expansion of biosimilars in various therapeutic areas, enabling greater access to effective therapies. Oncology (Dominant) vs. Chronic & Autoimmune Disorders (Emerging) Oncology remains the dominant application in the South Korea biosimilar contract-manufacturing market, characterized by a high volume of biosimilar products aimed at treating various types of cancers. The oncology segment benefits from robust support in research and development, with continuous innovations leading to new therapeutic options. Conversely, chronic & autoimmune disorders are emerging rapidly, demonstrating a growing market interest due to the rising cases of conditions such as rheumatoid arthritis and other autoimmune diseases. The diverse therapeutic needs and a push for cost-effective alternatives make this segment highly appealing for biosimilar manufacturers, indicating a proactive shift in market dynamics. ## Competitive Benchmarking The biosimilar contract-manufacturing market in South Korea is characterized by a dynamic competitive landscape, driven by increasing demand for cost-effective biologics and the growing acceptance of biosimilars among healthcare providers. Major players such as Samsung Biologics (KR), Lonza Group (CH), and Boehringer Ingelheim (DE) are strategically positioned to leverage their extensive manufacturing capabilities and technological expertise. Samsung Biologics (KR) focuses on expanding its production capacity and enhancing its service offerings, while Lonza Group (CH) emphasizes innovation through advanced bioprocessing technologies. Boehringer Ingelheim (DE) is actively pursuing partnerships to strengthen its market presence, indicating a trend towards collaborative strategies that enhance operational efficiencies and market reach.Key business tactics within this market include localizing manufacturing to reduce costs and optimize supply chains. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a variety of strategic approaches, as companies seek to differentiate themselves through unique value propositions and operational efficiencies. In October Samsung Biologics (KR) announced the completion of its new state-of-the-art manufacturing facility, which is expected to increase its production capacity by 30%. This expansion is strategically significant as it positions the company to meet the rising global demand for biosimilars, thereby enhancing its competitive edge in the market. The facility is designed to incorporate advanced automation and digital technologies, aligning with industry trends towards efficiency and scalability. In September Lonza Group (CH) entered into a strategic partnership with a leading biopharmaceutical company to co-develop a new biosimilar product. This collaboration is indicative of Lonza's commitment to innovation and its strategy to enhance its product portfolio. By leveraging its partner's expertise in drug development, Lonza aims to accelerate the time-to-market for new biosimilars, which could significantly impact its market share and revenue growth. In August Boehringer Ingelheim (DE) launched a new initiative focused on sustainability in its manufacturing processes. This initiative aims to reduce carbon emissions by 25% over the next five years, reflecting a growing trend towards environmentally responsible practices in the industry. Such moves not only enhance corporate reputation but also align with the increasing regulatory pressures for sustainability in biopharmaceutical manufacturing. As of November current competitive trends in the biosimilar contract-manufacturing market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in manufacturing processes. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation and efficiency. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, supply chain reliability, and innovative product offerings, suggesting a transformative shift in how companies position themselves in the market. ## Recent News & Developments Recent developments in the South Korea Biosimilar Contract Manufacturing Market have been significant, showcasing the country's prowess in biotechnology. Samsung BioLogics has been actively expanding its contract manufacturing capabilities, aiming to meet the increasing global demand for biosimilars. In October 2023, Celltrion announced a collaboration with a prominent European pharmaceutical company to enhance its biosimilar portfolio, reinforcing its position in the competitive landscape. Severance Hospital and the Korean Cancer Center Hospital have been integral in advancing clinical trials for biosimilars, ensuring regulatory compliance and safety. The market has seen a substantial growth in valuation, driven by innovations from Hanmi Pharmaceutical and Alteogen, who are investing heavily in Research and Development to optimize their offerings. Furthermore, Yuhan Corporation and SK Holdings are positioning themselves strategically through partnerships and technology sharing. In July 2022, LG Chem announced a merger with Ilyang Pharmaceutical to enhance production efficiencies and broaden its reach in biosimilar manufacturing. This collaborative environment is fostering a robust ecosystem that propels South Korea as a global leader in biomanufacturing and biosimilars, positioning companies like Medytox and DaeWoong Pharmaceutical favorably in the expanding market. ## Report Scope | MARKET SIZE 2024 | 115.93(USD Million) | | --- | --- | | MARKET SIZE 2025 | 137.84(USD Million) | | MARKET SIZE 2035 | 778.53(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 18.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Samsung Biologics (KR), Lonza Group (CH), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Wuxi Biologics (CN), Roche (CH), Amgen (US), Sandoz (CH) | | Segments Covered | Product, Production Technology, Application | | Key Market Opportunities | Emerging technologies in biomanufacturing enhance efficiency in the biosimilar contract-manufacturing market. | | Key Market Dynamics | Rising demand for biosimilars drives competitive contract-manufacturing partnerships amid evolving regulatory frameworks in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the projected market valuation for the South Korea biosimilar contract-manufacturing market by 2035?** A: The projected market valuation is $778.53 Million by 2035. **Q: What was the market valuation for the South Korea biosimilar contract-manufacturing market in 2024?** A: The market valuation was $115.93 Million in 2024. **Q: What is the expected CAGR for the South Korea biosimilar contract-manufacturing market during the forecast period 2025 - 2035?** A: The expected CAGR is 18.9% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the South Korea biosimilar contract-manufacturing market?** A: Key players include Samsung Biologics, Lonza Group, Boehringer Ingelheim, Fujifilm Diosynth Biotechnologies, Wuxi Biologics, Roche, Amgen, and Sandoz. **Q: What are the two main product segments in the South Korea biosimilar contract-manufacturing market?** A: The two main product segments are Recombinant Non-glycosylated Proteins and Recombinant Glycosylated Proteins. **Q: What was the valuation for the Recombinant Glycosylated Proteins segment in 2024?** A: The valuation for the Recombinant Glycosylated Proteins segment was $75.93 Million in 2024. **Q: What production technologies are utilized in the South Korea biosimilar contract-manufacturing market?** A: The production technologies include Mammalian and Non-Mammalian systems. **Q: What was the valuation for the Mammalian production technology segment in 2024?** A: The valuation for the Mammalian production technology segment was $69.56 Million in 2024. **Q: Which application segment had the highest valuation in 2024 within the South Korea biosimilar contract-manufacturing market?** A: The Chronic & Autoimmune Disorders application segment had the highest valuation at $29.0 Million in 2024. **Q: What is the projected growth for the Chronic & Autoimmune Disorders application segment by 2035?** A: The projected growth for the Chronic & Autoimmune Disorders application segment is expected to reach $205.78 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-biosimilar-contract-manufacturing-market-51866*